OGEN logo

Oragenics Inc.


OGEN: Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.


Show OGEN Financials

Consumer Interest
SEC Filings

Recent trades of OGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by OGEN's directors and management

Government lobbying spending instances

  • $10,000 Jul 19, 2021 Issue: Defense
  • $10,000 Apr 20, 2021 Issue: Defense
  • $50,000 Nov 02, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Oct 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $40,000 Jul 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $10,000 Jan 19, 2011 Issue: None
  • $10,000 Oct 18, 2010 Issue: Health Issues
  • $10,000 Jul 19, 2010 Issue: Health Issues
  • $10,000 Apr 16, 2010 Issue: Budget/Appropriations
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of OGEN in WallStreetBets Daily Discussion


Recent insights relating to OGEN

CNBC Recommendations

Recent picks made for OGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OGEN

Corporate Flights

Flights by private jets registered to OGEN